gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NVCTHealthcarePharmaceuticals

Nuvectis Pharma, Inc. Common Stock (NVCT)

$17.26−10.75%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$17.26▲ 171.38% in range
Nov 3, 2025Low $5.65 · High $28.53Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Nuvectis Pharma closed at $17.26 on Nov 4, down 10.75%, 39.5% below its 52-week closing high. Volume of 131.6K shares was 0.78× its 20-day average (below normal).

Split-adjusted performance: -13.8% over one month, +72.6% over six months, +171.4% over one year.

Short interest was 2.4M shares at the Oct 15 settlement, down 4.8% from the prior report (11.7% of float, 13.9 days to cover).

Market cap$563.4M32.6M shares
Revenue · quarter$0.00—
Diluted EPS$-0.30—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range5.65 – 28.53−39.5% from high
Volume131.6K0.78× 20-day avg
Volatility · 60d71.6%Annualised
Short % of float11.7%13.9 days to cover
Net cash$22.2MCash $22.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.0%1M −13.8%3M −8.3%6M +72.6%YTD +128.6%1Y +171.4%3Y +106.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum97
Revenue growth—
Net margin—
Value (low P/E)—
Size63

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.4M−4.8% vs prior
Days to cover13.9Settled Oct 15
% of float11.7%
Short vol. 10d68.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NVCTNuvectis Pharma$17.26−10.75%+72.6%———$563.4M
PBYIPUMA BIOTECHNOLOGY$10.76+5.28%+44.4%+7.8%14.5%20.8$555.4MCompare
ACRSAclaris Therapeutics$3.71−0.94%−22.5%−8.3%−1320.1%—$574.2MCompare
BCAXBicara Therapeutics$8.77−2.12%−63.1%———$580.3MCompare
DMACDiaMedica Therapeutics$10.80+8.00%+65.6%———$582.4MCompare
CLYMClimb Bio$9.38−3.79%−23.2%———$538.8MCompare
STTKShattuck Labs$5.36−2.01%−19.8%———$537.9MCompare
NGNENeurogene$26.85+0.67%−17.0%———$537.3MCompare
IRWDIronwood Pharmaceuticals, Inc. -$3.72+6.14%−23.1%+32.6%45.4%4.7$613.9MCompare

News about Nuvectis Pharma

All news →
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswire Inc. · 2d ago▲ PositiveNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockGlobeNewswire Inc. · Jun 30, 2026▲ PositiveNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingGlobeNewswire Inc. · Mar 31, 2026▲ Positive

Quick answers

What does Nuvectis Pharma do?
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology.
What is NVCT's market cap?
$563.44M, based on the Nov 4 close of $17.26.
Does Nuvectis Pharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NVCT is sold short?
2.4M shares, 11.7% of float, as of Oct 15, 2026.
What sector is NVCT in?
Healthcare, in the Pharmaceuticals industry.

About Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

HQ: Fort Lee, NJ13 employeesListed Feb 4, 2022nuvectis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology